Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 8,700 shares, a decline of 91.8% from the March 15th total of 105,600 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 3,830,000 shares, the days-to-cover ratio is presently 0.0 days.

Adial Pharmaceuticals Stock Up 106.2 %

Shares of ADIL stock opened at $2.33 on Thursday. Adial Pharmaceuticals has a 12 month low of $0.77 and a 12 month high of $14.00. The firm has a market cap of $3.87 million, a PE ratio of -0.41 and a beta of 1.48. The stock has a 50 day moving average of $1.48 and a 200-day moving average of $1.85.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Citadel Advisors LLC raised its stake in shares of Adial Pharmaceuticals by 1,156.2% in the third quarter. Citadel Advisors LLC now owns 265,062 shares of the company’s stock valued at $93,000 after purchasing an additional 243,962 shares in the last quarter. Armistice Capital LLC acquired a new position in shares of Adial Pharmaceuticals in the fourth quarter valued at $296,000. Renaissance Technologies LLC raised its stake in shares of Adial Pharmaceuticals by 748.8% in the second quarter. Renaissance Technologies LLC now owns 169,400 shares of the company’s stock valued at $227,000 after purchasing an additional 149,442 shares in the last quarter. Susquehanna International Group LLP raised its stake in shares of Adial Pharmaceuticals by 144.3% in the first quarter. Susquehanna International Group LLP now owns 222,283 shares of the company’s stock valued at $78,000 after purchasing an additional 131,287 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Adial Pharmaceuticals in the second quarter valued at $53,000. 16.41% of the stock is currently owned by institutional investors and hedge funds.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.